Study design (if review, criteria of inclusion for studies)
Randomized double-blind crossover trial.
Patients aged â¥12 years with CF with clinical or molecular evidence of residual CFTR function
Patients were randomized to 1 of 4 treatment sequences for two 4-week, double-blind crossover cycles (each divided into 2 weeks of ivacaftor treatment and placebo) followed by 8 weeks of open-label ivacaftor treatment.
The primary endpoint was absolute change from cycle baseline of percent predicted forced expiratory volume in 1 s (ppFEV(1)) after 2 weeks of treatment with ivacaftor relative to placebo.
Absolute change (SD) from study baseline in ppFEV(1) favored ivacaftor by 2.3 (1.0) percentage points (95% credible interval, 0.4-4.1) after 2 weeks of treatment. Absolute mean change (SD) from open-label baseline (defined as day 1 of the open-label ivacaftor treatment period) in ppFEV(1) after 8 weeks of treatment was 4.7 (4.2) percentage points (P<.0001). Safety of ivacaftor was consistent with that observed in prior studies.
Ivacaftor improved lung function during the double-blind and open-label treatment periods in patients with CF and CFTR mutations associated with residual CFTR function.